/
We are a clinical-stage specialty pharmaceutical company developing and commercializing therapies for the treatment of retinal diseases. We are developing KIO-301, with an initial focus on patients with later stages of vision loss due to retinitis pigmentosa (collectively including any and all sub-forms, "RP").
Revenue declined 100.0% YoY. The question is whether this is cyclical or a structural shift.
Free cash flow declined 218% versus the prior year, cash generation momentum has weakened. ROIC dropped from 15.27% to -47.91%, capital efficiency is deteriorating.
Profitability & Returns
Revenue (FY)
$0.00
▼ -100.0% YoY
Net Income (TTM)
-$11M
▼ -401.4% YoY
Op. Margin
—
ROIC
-53.97%
▼ -63.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$11M
▼ -217.8% YoY
Op. Cash Flow (TTM)
-$10M
▼ -216.4% YoY
Net Debt
-$13M
Net Cash Position
Cash & Equiv.
$14M
Continue Research